This trial is active, not recruiting.

Condition suicidal behaviour
Treatment clinical and neuropsychological assessment, blood and saliva samples
Sponsor University Hospital, Montpellier
Collaborator Créteil Hospital
Start date September 2001
End date September 2017
Trial size 1982 participants
Trial identifier NCT02858635, 7653


Suicide is a major health problem that causes annually a million death worldwide. In the stress-vulnerability model, suicidal behavior (SB) results from the interaction between an individual's predisposition and stressful condition. According to this model, individuals who carry a suicidal act when subjected to stress factors (environmental stress, depression, substance ...) are those which have a specific vulnerability.These vulnerabilities can be considered as clinical parameters (propensity to despair, aggressive and/or impulsive traits), neurobiological parameters (dysfunction of the serotonergic system, ...) and cognitive parameters (taking disadvantageous decision ...). Suicidal vulnerability is partly underpinned by genetic factors. The interest of current researches is to identify biomarkers that will improve the opportunities for early identification of subject with a risk for SB.

The four goals of this project are in the continuity of previous works team:

1. To determine whether combinations of the main serotonin-related genes may better contribute to the vulnerability to SB, than when they are considered independently.

2. To assess whether the associations between these genes and SB are modulated by childhood trauma, life events and stress response associated with these environmental factors.

3. To test the value of combined clinical, neuropsychological and genetic factor for suicide prevention, in a prospective study, in particularity impulsivity and gene gene interaction.

4. To investigate the association between events in real life (using ecological momentary assessment) and emotional response and suicidal ideation.

The investigators propose to use a multidisciplinary approach to answer these questions and, hence, be able to identify new prevention strategies for SB.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Clinical and neuropsychological assessment. Blood and saliva samples in order to answer objectives study.
clinical and neuropsychological assessment, blood and saliva samples
Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.

Primary Outcomes

occurrence of suicide attempt
time frame: up to 6 months

Secondary Outcomes

suicidal ideation
time frame: up to 7 days
number of suicide attempt
time frame: 1 hour
type of suicide attempt
time frame: 1 hour
lethality of suicide attempt
time frame: 1 hour
time frame: 1 hour
time frame: 1 hour
time frame: 1 hour
psychological pain
time frame: 1 hour

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - personal history of suicide attempt - French Caucasian Western Europe and specifically have all four grandparents from a country in Western Europe (for genetics purposes) - able to understand nature, aims, and methodology oh the study - do not emphasize to leave during the time-study. Exclusion Criteria: - Pregnancy - Not able to speak, read and understand French - Patient on protective measures (guardianship or trusteeship)

Additional Information

Official title Molecular Genetics of Suicidal Behavior: Study of Association Between Aggressive Impulsiveness and Genes of the Serotoninergic System
Description Transversal study: 1500 patients with a personal history of suicide attempt will be recruited. Clinical, biological and neuropsychological assessments will be performed. The first objective of the study is to replicate the results already obtained regarding the association between serotonergic system genes and suicidal behaviour. The allele frequencies for different markers tested in suicidal and in control subjects with no history of suicidal behaviour will be compared. The patients that will be recruited will be compared to the control population already recruited for another project. Prospective study: 554 patients hospitalized for a suicide attempt will will be evaluated, each 6 month, during the 2-years period of the study. Clinical, biological and neuropsychological assessments will be performed. At the end of the inclusion visit, 60 participants will be assessed using ecological momentary assessment(ESM). They will be instructed to carry a smartphone with them for one week, and to record at each alarm signal daily life events, negative emotions, psychological pain, suicidal ideas, and specific attributions to these events. Participants will be signalled five times a day during the period. Subjects will be contacted by telephone halfway through the assessment period to monitor and encourage compliance.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by University Hospital, Montpellier.